Lyophilized pharmaceutical compositions for vaginal delivery
US11026883B2 · kind B2 · utility
1Cited by
13References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 13, 2017 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Oct 13, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a solid lyophilized vaginal dosage form that can have an effective amount of at least one active ingredient, a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form, and at least one polymeric mucoadhesive matrix forming agent. The dosage form can have a pH of about 4.0 to 5.0, and can disintegrate within 120 seconds after being contacted with a vaginal mucosa. A method of delivering an active ingredient to the vaginal mucosa using the disclosed solid dosage form is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.